SAB Biotherapeutics shareholders approve 24.18M share increase and Series B conversion at less than minimum price

SAB Biotherapeutics, Inc.

Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.
Approved issuance of over 19.99% of outstanding common stock upon Series B Preferred conversion at less than Nasdaq minimum price, deemed a potential change of control.
Proposal 1 (conversion) passed with 5,502,026 votes for, 515,275 against, 35,744 abstentions.
Proposal 2 (plan amendment) passed with 5,089,862 votes for, 951,598 against, 11,585 abstentions.
Approximately 54.5% of outstanding shares were present, forming a quorum.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.